Latest Content

Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.

Pharmacists are moving beyond order verification into patient education, adverse effect mitigation, and parts of toxicity triage in bispecific care.

Weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis in the PREVAIL study.

Meta-analysis suggests off-label upadacitinib drives major alopecia areata hair regrowth and SALT score gains, but phase 3 trials show lower responses.

Kidney Week 2026 brought strong IgAN data, looked back on 5 years of value-based kidney care, and highlighted evidence of persistent CKD care gaps.

Oncologists reveal why breakthrough cancer drugs still stall—referral gaps, payer delays, caregiver needs, and pharmacy bottlenecks reshape access across tumor types.

Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.